Active substanceMometasoneMometasone
Similar drugsTo uncover
  • Avecourt
    ointment externally 
    PATENT-FARM, CJSC     Russia
  • Asmanex® Twistheiler®
    powder d / inhal. 
  • Galazolin Allergo
    spray nazal. 
  • Gistan-N
    cream externally 
  • Desrinite
    spray nazal. 
  • Momat
    ointment externally 
  • Momat
    cream externally 
  • Momo Reno
    spray nazal. 
  • Momederm®
    ointment externally 
    VALEANT, LLC     Russia
  • Momederm®
    solution externally 
    VALEANT, LLC     Russia
  • Mometasone
    ointment externally 
    VERTEKS, AO     Russia
  • Mometasone Sandoz®
    spray nazal. 
    Sandoz d.     Slovenia
  • Mometasone-Akrihin
    cream externally 
    AKRIKHIN HFK, JSC     Russia
  • Monovo
    cream externally 
    RAYFARM, LLC     Russia
  • Monovo
    ointment externally 
    Almiral Hermal GmbH     Germany
  • Nazonex®
    spray nazal. 
  • Nosephrine®
    spray nazal. 
    VERTEKS, AO     Russia
  • Silkaren®
    cream externally 
    VERTEKS, AO     Russia
  • Elokom®
    ointment externally 
  • Elokom®
    cream externally 
  • Elokom® Lotion
    solution externally 
  • Dosage form: & nbspcream for external use
    Composition:

    100 g of cream contain:

    active substance: mometasone furoate - 0.1 g;

    ExcipientsParaffin (white soft paraffin), white beeswax, propylene glycol monostearate, stearyl alcohol, cetomacrogol, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, purified water.

    Description:The cream is white.
    Pharmacotherapeutic group:Glucocorticosteroid for topical application
    ATX: & nbsp

    R.01.A.D.09   Mometasone

    Pharmacodynamics:

    Mometasone is a synthetic glucocorticosteroid (GCS), which possesses an anti-inflammatory, antipruritic and antiexudative action. SCS induces the release of phospholipase-inhibiting proteins A2 and known collectively as lipocortins that control the biosynthesis of inflammatory mediators such as prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid.

    Pharmacokinetics:

    Absorption of cream Momat is insignificant. After 8 hours after the single application on intact skin (without occlusive dressings) detected in the systemic circulation of about 0.4% of active compound. Mometasone intensively metabolized in the liver, is excreted mainly by the kidneys and in an insignificant quantity with bile.

    Indications:

    Inflammation and itching in dermatoses that respond to glucocorticosteroid therapy.

    Contraindications:

    - Hypersensitivity to any component of the drug or to GCS.

    - Pink acne, perioral dermatitis.

    - Bacterial, viral (Herpes simplex, chickenpox, Herpes zoster) or fungal infection of the skin.

    - Tuberculosis, syphilis.

    - Post-vaccination reactions.

    - Pregnancy (treatment of extensive skin areas, long-term treatment).

    - Lactation period (use in large doses and / and for a long time).

    Carefully:

    Application to the skin and intertriginoznuyu skin, the use of occlusive dressings, as well as treatment of large areas of the skin and / or long-term treatment (especially in children).

    Pregnancy and lactation:

    The safety of the use of mometasone furoate during pregnancy and lactation has not been studied.

    GCS penetrate the placental barrier. Long-term treatment and use of large doses during pregnancy should be avoided due to the threat of adverse effects on fetal development.

    GCS is excreted in breast milk.In the event that the use of GCS is expected in large doses and / or for a long time, breastfeeding should be discontinued.

    Dosing and Administration:

    Outwardly.

    A thin layer of cream Momat is applied to the affected areas of the skin once a day. The duration of the course of treatment is determined by its effectiveness, as well as the patient's tolerance, the presence and severity of side effects.

    Side effects:

    Rarely - irritation and dry skin, burning sensation, itching, folliculitis, hypertrichosis, acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, signs of skin atrophy, striae, sweating. Less than 1% of cases - the formation of papules, pustules.

    When external forms of SCS are used for a long time and / or for the treatment of large areas of the skin, or with the use of occlusive dressings, especially in children and adolescents, side effects typical of SCS of systemic action, including adrenal insufficiency and Cushing's syndrome, may occur.

    Overdose:

    Symptoms: oppression of the hypothalamic-pituitary-adrenal system, including secondary adrenal insufficiency.

    Treatment: symptomatic, if necessary - correction of electrolyte imbalance, drug withdrawal (with prolonged therapy - gradual abolition).

    Interaction:

    Studies of the drug interaction of Momat cream with other drugs have not been conducted.

    Special instructions:

    When applied to large areas of the skin for a long time, especially with the application of occlusive dressings, it is possible to develop a systemic action of GCS. Given this, patients should be observed in terms of signs of suppression of the hypothalamic-pituitary-adrenal system and the development of Cushing's syndrome. You should avoid getting the cream in the eyes.

    Propylene glycol, which is part of the preparation, may cause irritation at the site of application. In such cases, you should stop using the cream of Momat and prescribe the appropriate treatment.

    It should be borne in mind that the GCS is able to change the manifestations of certain skin diseases, which can make it difficult to diagnose. In addition, the use of GCS may be the cause of delayed wound healing.

    With prolonged therapy with SCS, sudden discontinuation of therapy can lead to the development of a rebound syndrome, manifested in the form of dermatitis with intense reddening of the skin and a burning sensation.Therefore, after a long course of treatment, the drug should be canceled gradually, for example, by switching to an intermittent treatment regimen before it is completely discontinued.

    Pediatric Use

    Due to the fact that the ratio of surface area and body weight is greater in children than in adults, children are at greater risk of suppressing the function of the hypothalamic-pituitary-adrenal system and the development of Cushing's syndrome with any local GCS.

    Long-term GCS treatment of children can lead to disruption of their growth and development.

    Children should receive a minimum dose of the drug sufficient to achieve the effect.

    Form release / dosage:

    Cream for external use 0,1%.

    Packaging:

    For 5 g or 15 g in an aluminum tube, having a nozzle with a closed end, with a lid having a piercing tip.

    Each tube together with the instruction for use is placed in a cardboard box.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C. Do not freeze.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-005537/07
    Date of registration:28.12.2007
    Expiration Date:Unlimited
    The owner of the registration certificate:Glenmark Pharmaceuticals Co., Ltd.Glenmark Pharmaceuticals Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspGLENMARK IMPEX LLCGLENMARK IMPEX LLCRussia
    Information update date: & nbsp26.04.2016
    Illustrated instructions
      Instructions
      Up